References
- Stenman U-H, Koivunen E., Itkonen O. Biology and function of tumour-associated trypsin inhibitor, TATI. Scand J Clin Lab Invest 1991; 51(Suppl 207)5–9
- Halila H., Lehtovirta P., Stenman U-H. Tumor-associated trypsin inhibitor in ovarian cancer. Br J Cancer 1988; 57: 304–7
- Paavonen J., Lehtinen M., Lento M., Aine R., Räsänen L., Stenman U-H. Concentrations of tumor-associated trypsín inhíbítor and C-reactive protein in serum in pelvic inflammatory disease. Clin Chem 1989; 35: 869–71
- Freeman T. C., Playford R. J., Quinn C., Beardshall K., Poulter L., Young J., Calam J. Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice. Gut 1990; 31: 1318–23
- Bohe H., Bohe M., Lindström C., Ohlsson K. Immunohistochemical demonstration of pancreatic secretory trypsin inhibitor in normal and neoplastic colonic mucosa. J Clin Pathol 1990; 43: 901–4
- Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 24(Suppl 170)2–5
- Fuchs D., Hausen A., Reibnegger G., Reissgl H., Schönitzer D., Spira T., Wachter H. Urinary neopterin in the diagnosis of acquired immune deficiency syndrome. Eur J Clin Mirobiol 1984; 3: 70–1
- Stenman U-H, Huhtala M-L, Koistinen R., Seppälä M. Immunochemical demonstration of an ovarian cancer associated urinary peptide. Int J Cancer 1982; 30: 53–7
- Gomes P., du Boulay C., Smith C. L., Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92–5
- Myren J., Bouchier I. AD, Watkinson G., Softley A., Clamp S. E., de Dombal F. T. The OMGE Multinational Inflammatory Bowel Disease Survey A further report on 2657 cases. Scand J Gastroenterol 1984; 23(Suppl 95)1–27
- Metz C. Basic principles of ROC analysis. Seminars in Nuclear Medicine 1978; 4: 283–98
- Boirivant M., Leoni M., Tariciotti D., Fais S., Squarcia O., Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. J Clin Gastroenterol. 1988; 10: 401–5
- Andre C., Descos L., Andre F., Vignal J., Landais P., Fermanian J. Biological measurements of Crohn's disease - a reassessment. Hepato-gastroenterol 1985; 32: 135–7
- Prior C., Bollbach R., Fuchs D., Hausen A., Judmaier G., Niederwieser D., Reibnegger G., Rotthauwe H., Werner E., Wachter H. Urinary neopterin a marker of clinical activity in patients with Crohn's disease. CUn Chim Acta 1986; 155: 11–22
- Wright J., Alp M., Young G., Tigler-Wybrandi N. Predictors of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci 1987; 32: 164–70
- Fagen E., Dycke R., Maton P., Hodgson H., Chadwick V., Petrie A. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 12: 351–9
- Niederwieser D., Fuchs D., Hausen A., Judmaier G., Reibnegger G., Wachter H., Huber C. Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitis. Immunobiology 1985; 170: 320–6
- Fishbach W., Becker W., Mössner J., Koch W., Reiners C. Faecal alpha)-antitrypsin and excretion of indium-granulocytes in assessment of disease activity in chronic inflammatory bowel disease. Gut 1987; 28: 386–393
- Best W. R., Becktel J. M., Singleton J. W., Kern F. Development of a Crohn's disease activity index: national co-operative Crohn's disease study. Gastroenterology 1976; 70: 439–44
- van Hees P. AM, van Elteren P. H., van Lier H. JJ, van Tongeren J. HM. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 279–86
- Brignola C., Assuero Lanfranchi G., Campieri M., Bazzocchi G., Devoto M., Boni P., Farruggia P., Veggetti S., Tragnone A. Importance of laboratory parameters in the evaluation of Crohn's disease activity. J Clin Gastroenterol 1986; 8: 245–8